Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) International — Reported Sales Growth (%) (%)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Latest, Q3 2026
12.2%
Period ended Sep 30, 2026
Change on a year earlier
-4.7 pts
16.9% in Q3 2025
History
39 quarters
Since Q1 2017
Sources
39
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) International — Reported Sales Growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 12.2% | -4.7 pts | SEC Filing (0001628280-26-066601) ↗ |
| Q2 2026 | Jun 30, 2026 | 12.1% | -1.6 pts | SEC Filing (0001628280-26-048377) ↗ |
| Q1 2026 | Mar 31, 2026 | 25.2% | +20.6 pts | SEC Filing (0001628280-26-025365) ↗ |
| Q4 2025 | Dec 31, 2025 | 16.3% | -3.2 pts | SEC Filing (0001628280-26-002982) ↗ |
| Q3 2025 | Sep 30, 2025 | 16.9% | +7.7 pts | SEC Filing (0001628280-25-045049) ↗ |
| Q2 2025 | Jun 30, 2025 | 13.7% | +4.3 pts | SEC Filing (0001628280-25-035135) ↗ |
| Q1 2025 | Mar 31, 2025 | 4.6% | -7.9 pts | SEC Filing (0001628280-25-017924) ↗ |
| Q4 2024 | Dec 31, 2024 | 19.5% | +1.9 pts | SEC Filing (0001628280-25-002092) ↗ |
| Q3 2024 | Sep 30, 2024 | 9.2% | -14.6 pts | SEC Filing (0001628280-24-042893) ↗ |
| Q2 2024 | Jun 30, 2024 | 9.4% | -10.4 pts | SEC Filing (0001628280-24-032182) ↗ |
| Q1 2024 | Mar 31, 2024 | 12.5% | -1.2 pts | SEC Filing (0001628280-24-016497) ↗ |
| Q4 2023 | Dec 31, 2023 | 17.6% | +17.2 pts | SEC Filing (0001628280-24-002009) ↗ |
| Q3 2023 | Sep 30, 2023 | 23.8% | +24.5 pts | SEC Filing (0001628280-23-034544) ↗ |
| Q2 2023 | Jun 30, 2023 | 19.8% | +18.9 pts | SEC Filing (0001628280-23-025156) ↗ |
| Q1 2023 | Mar 31, 2023 | 13.7% | +7.7 pts | SEC Filing (0001628280-23-012020) ↗ |
| Q4 2022 | Dec 31, 2022 | 0.4% | -13.2 pts | SEC Filing (0001628280-23-001516) ↗ |
| Q3 2022 | Sep 30, 2022 | -0.7% | -11.6 pts | SEC Filing (0001628280-22-026588) ↗ |
| Q2 2022 | Jun 30, 2022 | 0.9% | -74.2 pts | SEC Filing (0001104659-22-081006) ↗ |
| Q1 2022 | Mar 31, 2022 | 6.0% | -8.3 pts | SEC Filing (0001104659-22-047560) ↗ |
| Q4 2021 | Dec 31, 2021 | 13.6% | +16.9 pts | SEC Filing (0001104659-22-007648) ↗ |
| Q3 2021 | Sep 30, 2021 | 10.9% | +9.0 pts | SEC Filing (0001104659-21-127874) ↗ |
| Q2 2021 | Jun 30, 2021 | 75.1% | +109.3 pts | SEC Filing (0001104659-21-094680) ↗ |
| Q1 2021 | Mar 31, 2021 | 14.3% | +17.3 pts | SEC Filing (0001104659-21-052205) ↗ |
| Q4 2020 | Dec 31, 2020 | -3.3% | -11.0 pts | SEC Filing (0001104659-21-007942) ↗ |
| Q3 2020 | Sep 30, 2020 | 1.9% | -4.4 pts | SEC Filing (0001104659-20-116611) ↗ |
| Q2 2020 | Jun 30, 2020 | -34.2% | -35.9 pts | SEC Filing (0001104659-20-083929) ↗ |
| Q1 2020 | Mar 31, 2020 | -3.0% | -4.8 pts | SEC Filing (0001104659-20-047187) ↗ |
| Q4 2019 | Dec 31, 2019 | 7.7% | -0.2 pts | SEC Filing (0001104659-20-005717) ↗ |
| Q3 2019 | Sep 30, 2019 | 6.3% | -5.7 pts | SEC Filing (0001104659-19-054283) ↗ |
| Q2 2019 | Jun 30, 2019 | 1.7% | -18.0 pts | SEC Filing (0001104659-19-040664) ↗ |
| Q1 2019 | Mar 31, 2019 | 1.8% | -21.6 pts | SEC Filing (0001104659-19-021809) ↗ |
| Q4 2018 | Dec 31, 2018 | 7.9% | -238.3 pts | SEC Filing (0001104659-19-002848) ↗ |
| Q3 2018 | Sep 30, 2018 | 12.0% | -230.5 pts | SEC Filing (0001104659-18-062380) ↗ |
| Q2 2018 | Jun 30, 2018 | 19.7% | -199.5 pts | SEC Filing (0001104659-18-045642) ↗ |
| Q1 2018 | Mar 31, 2018 | 23.4% | -198.1 pts | SEC Filing (0001104659-18-024701) ↗ |
| Q4 2017 | Dec 31, 2017 | 246.2% | – | SEC Filing (0001104659-18-003691) ↗ |
| Q3 2017 | Sep 30, 2017 | 242.5% | – | SEC Filing (0001104659-17-062667) ↗ |
| Q2 2017 | Jun 30, 2017 | 219.2% | – | SEC Filing (0001104659-17-045904) ↗ |
| Q1 2017 | Mar 31, 2017 | 221.5% | – | SEC Filing (0001104659-17-024344) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) International — Reported Sales Growth (%) (%), quarterly Q1 2017–Q3 2026 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/md-sh-yoy-rep-intl
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.